Abstract
Background COVID-19 continues to spread globally, this study is the first to explore the impact of COVID-19 on the treatment and prognosis of rural and urban acute myocardial infarction (AMI) in developing country.Methods A total of 128 patients with AMI in our hospital during the COVID-19 pandemic (January 25, 2020-March 24, 2020) were enrolled. As a control group, a total of 197 patients diagnosed with AMI from November 25, 2019 to January 24, 2020 were selected. A total of 1 year of follow-up was performed. In addition to basic clinical data, this study focused on the treatment time, Killip class and hospital stay, the event of interest was defined as MACE (all-cause death, reinfarction, new congestive heart failure).Results Compared with Before COVID-19 group, the proportion of killip class≥2 was significantly higher in During COVID-19 group in AMI Total. In Rural AMI, hospital stay and the proportion of killip class≥2 were increased in During COVID-19 group. In STEMI Total and Rural STEMI, the treatment time in During COVID-19 group was longer than that in Before COVID-19 group, while only S to D Total and D to B were extended in Urban STEMI. The proportion of Invasive treatment time within 24 hours in NSTEMI patients was obviously lowered in During COVID-19 group. In AMI Total and Rural AMI, MACE and all-cause mortality were increased in During COVID-19 group compared with Before COVID-19 group. Through Kaplan-Meier analysis, it was found that the survival and the occurrences of MACE in AMI Total and Rural AMI were significantly higher in During COVID-19 group.Conclusion COVID-19 pandemic can lead to delayed treatment and worse prognosis in AMI patients, and rural areas seem to be more worrying.